113 related articles for article (PubMed ID: 34547626)
1. Cox15 is a novel oncogene that required for lung cancer cell proliferation.
Zhang C; Li N; Liu YY; Yuan T; Yang S; Wang XP
Biochem Biophys Res Commun; 2021 Nov; 578():70-76. PubMed ID: 34547626
[TBL] [Abstract][Full Text] [Related]
2. Luteolin inhibits the Nrf2 signaling pathway and tumor growth in vivo.
Chian S; Thapa R; Chi Z; Wang XJ; Tang X
Biochem Biophys Res Commun; 2014 May; 447(4):602-8. PubMed ID: 24747074
[TBL] [Abstract][Full Text] [Related]
3. EZH2-mediated Puma gene repression regulates non-small cell lung cancer cell proliferation and cisplatin-induced apoptosis.
Liu H; Li W; Yu X; Gao F; Duan Z; Ma X; Tan S; Yuan Y; Liu L; Wang J; Zhou X; Yang Y
Oncotarget; 2016 Aug; 7(35):56338-56354. PubMed ID: 27472460
[TBL] [Abstract][Full Text] [Related]
4. LKB1 and KEAP1/NRF2 Pathways Cooperatively Promote Metabolic Reprogramming with Enhanced Glutamine Dependence in
Galan-Cobo A; Sitthideatphaiboon P; Qu X; Poteete A; Pisegna MA; Tong P; Chen PH; Boroughs LK; Rodriguez MLM; Zhang W; Parlati F; Wang J; Gandhi V; Skoulidis F; DeBerardinis RJ; Minna JD; Heymach JV
Cancer Res; 2019 Jul; 79(13):3251-3267. PubMed ID: 31040157
[TBL] [Abstract][Full Text] [Related]
5. Mutant p53 confers chemoresistance in non-small cell lung cancer by upregulating Nrf2.
Tung MC; Lin PL; Wang YC; He TY; Lee MC; Yeh SD; Chen CY; Lee H
Oncotarget; 2015 Dec; 6(39):41692-705. PubMed ID: 26497680
[TBL] [Abstract][Full Text] [Related]
6. Interplay of MKP-1 and Nrf2 drives tumor growth and drug resistance in non-small cell lung cancer.
Wang H; Liu K; Chi Z; Zhou X; Ren G; Zhou R; Li Y; Tang X; Wang XJ
Aging (Albany NY); 2019 Dec; 11(23):11329-11346. PubMed ID: 31811110
[TBL] [Abstract][Full Text] [Related]
7. Apatinib triggers autophagic and apoptotic cell death via VEGFR2/STAT3/PD-L1 and ROS/Nrf2/p62 signaling in lung cancer.
Xie C; Zhou X; Liang C; Li X; Ge M; Chen Y; Yin J; Zhu J; Zhong C
J Exp Clin Cancer Res; 2021 Aug; 40(1):266. PubMed ID: 34429133
[TBL] [Abstract][Full Text] [Related]
8. Dimethyl fumarate and the oleanane triterpenoids, CDDO-imidazolide and CDDO-methyl ester, both activate the Nrf2 pathway but have opposite effects in the A/J model of lung carcinogenesis.
To C; Ringelberg CS; Royce DB; Williams CR; Risingsong R; Sporn MB; Liby KT
Carcinogenesis; 2015 Jul; 36(7):769-81. PubMed ID: 25939751
[TBL] [Abstract][Full Text] [Related]
9. Oxidative stress-regulated lentiviral TK/GCV gene therapy for lung cancer treatment.
Leinonen HM; Ruotsalainen AK; Määttä AM; Laitinen HM; Kuosmanen SM; Kansanen E; Pikkarainen JT; Lappalainen JP; Samaranayake H; Lesch HP; Kaikkonen MU; Ylä-Herttuala S; Levonen AL
Cancer Res; 2012 Dec; 72(23):6227-35. PubMed ID: 23041549
[TBL] [Abstract][Full Text] [Related]
10. RNAi-mediated silencing of nuclear factor erythroid-2-related factor 2 gene expression in non-small cell lung cancer inhibits tumor growth and increases efficacy of chemotherapy.
Singh A; Boldin-Adamsky S; Thimmulappa RK; Rath SK; Ashush H; Coulter J; Blackford A; Goodman SN; Bunz F; Watson WH; Gabrielson E; Feinstein E; Biswal S
Cancer Res; 2008 Oct; 68(19):7975-84. PubMed ID: 18829555
[TBL] [Abstract][Full Text] [Related]
11. Brusatol enhances the efficacy of chemotherapy by inhibiting the Nrf2-mediated defense mechanism.
Ren D; Villeneuve NF; Jiang T; Wu T; Lau A; Toppin HA; Zhang DD
Proc Natl Acad Sci U S A; 2011 Jan; 108(4):1433-8. PubMed ID: 21205897
[TBL] [Abstract][Full Text] [Related]
12. Global downstream pathway analysis reveals a dependence of oncogenic NF-E2-related factor 2 mutation on the mTOR growth signaling pathway.
Shibata T; Saito S; Kokubu A; Suzuki T; Yamamoto M; Hirohashi S
Cancer Res; 2010 Nov; 70(22):9095-105. PubMed ID: 21062981
[TBL] [Abstract][Full Text] [Related]
13. CBX4 promotes the proliferation and metastasis via regulating BMI-1 in lung cancer.
Hu C; Zhang Q; Tang Q; Zhou H; Liu W; Huang J; Liu Y; Wang Q; Zhang J; Zhou M; Sheng F; Lai W; Tian J; Li G; Zhang R
J Cell Mol Med; 2020 Jan; 24(1):618-631. PubMed ID: 31724308
[TBL] [Abstract][Full Text] [Related]
14. The effects of NRF2 modulation on the initiation and progression of chemically and genetically induced lung cancer.
Tao S; Rojo de la Vega M; Chapman E; Ooi A; Zhang DD
Mol Carcinog; 2018 Feb; 57(2):182-192. PubMed ID: 28976703
[TBL] [Abstract][Full Text] [Related]
15. SIRT5 facilitates cancer cell growth and drug resistance in non-small cell lung cancer.
Lu W; Zuo Y; Feng Y; Zhang M
Tumour Biol; 2014 Nov; 35(11):10699-705. PubMed ID: 25070488
[TBL] [Abstract][Full Text] [Related]
16. Nrf2 promotes progression of non-small cell lung cancer through activating autophagy.
Wang J; Liu Z; Hu T; Han L; Yu S; Yao Y; Ruan Z; Tian T; Huang T; Wang M; Jing L; Nan K; Liang X
Cell Cycle; 2017 Jun; 16(11):1053-1062. PubMed ID: 28402166
[TBL] [Abstract][Full Text] [Related]
17. LncRNA LINC00680 promotes lung adenocarcinoma growth via binding to GATA6 and canceling GATA6-mediated suppression of SOX12 expression.
Sun X; Wang R; Tan M; Tian X; Meng J
Exp Cell Res; 2021 Aug; 405(1):112653. PubMed ID: 34029572
[TBL] [Abstract][Full Text] [Related]
18. Consumption of S-allylcysteine inhibits the growth of human non-small-cell lung carcinoma in a mouse xenograft model.
Tang FY; Chiang EP; Pai MH
J Agric Food Chem; 2010 Oct; 58(20):11156-64. PubMed ID: 20866043
[TBL] [Abstract][Full Text] [Related]
19. Serous IFNA3 predicts unfavorable prognosis in lung cancer via abnormal activation of AKT signaling.
Ge Q; Cong P; Ji Y
IUBMB Life; 2019 Nov; 71(11):1806-1814. PubMed ID: 31419016
[TBL] [Abstract][Full Text] [Related]
20. An innovative NRF2 nano-modulator induces lung cancer ferroptosis and elicits an immunostimulatory tumor microenvironment.
Hsieh CH; Hsieh HC; Shih FS; Wang PW; Yang LX; Shieh DB; Wang YC
Theranostics; 2021; 11(14):7072-7091. PubMed ID: 34093872
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
